Roivant Sciences

Roivant to Report Financial Results for the Quarter Ended December 31, 2021 on Monday, February 14, 2022

Retrieved on: 
Monday, February 7, 2022
GLOBE, Conference, Investor, NEW, Patient, U.S. Securities and Exchange Commission, Truist Financial, Roivant Sciences, Environment, Webcast, Risk, Pharmaceutical industry, Risk management

ET on Monday, February 14, 2022 to report its third quarter 2021 financial results and provide a corporate update.

Key Points: 
  • ET on Monday, February 14, 2022 to report its third quarter 2021 financial results and provide a corporate update.
  • A webcast of the call will also be available under Events & Presentations in the Investors section of theRoivantwebsite at https://investor.roivant.com/news-events/events .
  • Roivant also announced its participation in the following upcoming investor conferences:
    SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 1:00 p.m.
  • Roivant assumes no obligation to update forward-looking statements contained in the webcast as the result of new information or future events or developments.

Roivant to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, January 25, 2022
Risk, Roivant Sciences, NEW, Investor, Securities Exchange Act of 1934, U.S. Securities and Exchange Commission, Securities Act of 1933, Environment, Patient, GLOBE, Conference, Communications satellite, Audit, Risk management

ET

Key Points: 
  • ET
    A live webcast of each presentation will be available under Events & Presentations on the Investors section of the Roivant website at https://investor.roivant.com/news-events/events and an archived recording of the presentations will be available for 30 days.
  • Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity.
  • Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch 'Vants' nimble and focused biopharmaceutical and health technology companies.
  • The words may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

TandemAI Announces Expansion of Senior Leadership Team

Retrieved on: 
Tuesday, January 18, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Roivant Sciences, Chemistry, Technology, NIH, Harvard University, Biotechnology, University, Lanny, MBA, NASDAQ, CEO, Partner (business rank), Chicago (franchise), Berkeley, Time, Therapy, Silicon, Physics, Drug discovery, Director, Board, Acquisition, Management, Pharmaceutical industry, Fine chemical, Gordian, Gordian Ventures, TandemAI, GORDIAN VENTURES, TANDEMAI

TandemAI, a technology company focused on transforming drug discovery infrastructure, today announced two key appointments to its senior leadership team.

Key Points: 
  • TandemAI, a technology company focused on transforming drug discovery infrastructure, today announced two key appointments to its senior leadership team.
  • Dr. Pan will be based in New York and will continue to expand the computational platform team that will develop a broad range of applications for drug discovery.
  • Albert and Lanny bring a wealth of technical expertise, and business experience, respectively to TandemAI, said Jeff He, MBA, co-founder and CEO of TandemAI.
  • I look forward to working with Jeff, Albert and the TandemAI team to realize that vision.

Dermavant Presents New Patient Satisfaction Data from PSOARING 3 Long Term Extension Trial of Tapinarof in Adults with Plaque Psoriasis at the 2022 Winter Clinical Dermatology Conference

Retrieved on: 
Saturday, January 15, 2022
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, People, Atopic dermatitis, Ageing, New Drug Application, Roivant Sciences, Patient, Research, Vitiligo, Week, Conference, Acne, Psoriasis, LinkedIn, Dermatitis, Perception, Inflammatory bowel disease, Safety, Adult, PGA, Patient satisfaction, QD, Obesity, Hypertension, Skin, National Psoriasis Foundation, Oslo bid for the 2022 Winter Olympics, Diabetes, Efficiency, Quality of life, Depression, Therapy, Risk, Twitter, FDA, Physician, Pharmaceutical industry, Medical device, Dermavant’s Phase 3 Program for Tapinarof in Psoriasis, Psoriasis, Dermavant, DERMAVANT’S PHASE 3 PROGRAM FOR TAPINAROF IN PSORIASIS, PSORIASIS, DERMAVANT

These results were presented during the 2022 Winter Clinical Dermatology Conference, held January 14-19 in Koloa, Hawaii.

Key Points: 
  • These results were presented during the 2022 Winter Clinical Dermatology Conference, held January 14-19 in Koloa, Hawaii.
  • Dermavants pivotal Phase 3 clinical program for tapinarof in adult plaque psoriasis consists of PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980), as well as PSOARING 3 (NCT04053387), a long-term extension study.
  • PSOARING 3 was a long-term, open-label, extension study to evaluate the safety and efficacy of tapinarof cream, 1% for the treatment of plaque psoriasis in adults.
  • The company has reported positive Phase 3 results for tapinarof cream in adult patients with plaque psoriasis.

Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021

Retrieved on: 
Monday, January 10, 2022
Infertility, Pain, Man, LinkedIn, Gonadotropin-releasing hormone, FDA, Health care, Webcast, Roivant Sciences, Total, New Drug Application, European Commission, Female, Pregnancy, Union, Private Securities Litigation Reform Act, Medication, Woman, Norethisterone, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Adoption, SEC, Gedeon Richter, Endometriosis, Patient, Uterine fibroid, Food, Therapy, NYSE, Risk, Twitter, GLOBE, Royal commission, ORGOVYX, Sumitomo Dainippon Pharma, Growth, Testosterone, Marketing, Conference, Adult, Relugolix, Review, Prostate cancer, U.S. Securities and Exchange Commission, Fossil fuel, Pharmaceutical industry, Fine chemical, Audit, Pfizer

Furthermore, this press release includes information regarding Myovant Sciences preliminary financial results for the third fiscal quarter ended December 31, 2021.

Key Points: 
  • Furthermore, this press release includes information regarding Myovant Sciences preliminary financial results for the third fiscal quarter ended December 31, 2021.
  • Myovant Sciences is currently in the process of finalizing its financial results for the third fiscal quarter ended December 31, 2021, and the preliminary financial results presented in this press release are based only on preliminary information available to Myovant Sciences as of January 10, 2022.
  • These preliminary financial results should not be viewed as a substitute for audited consolidated financial statements prepared in accordance with U.S. GAAP, and undue reliance should not be placed on Myovant Sciences preliminary financial results.
  • Myovant Sciences independent registered public accounting firm has not audited or reviewed the preliminary financial results included in this press release or expressed any opinion or other form of assurance on such preliminary financial results.

Kriya Expands Gene Therapy Pipeline and Establishes Its Rare Disease Therapeutic Area Division With the Acquisition of Warden Bio

Retrieved on: 
Friday, January 7, 2022
Oncology, Health, Genetics, Pharmaceutical, Optical, Biotechnology, Therapy, GSD, Acquisition, Degenerative disease, Glycogen, Roivant Sciences, Research, Patient, Ophthalmology, Elon University, Silicon, Glycogen storage disease type II, Medical genetics, Pierre Geneves, Duke University, Division, AAV, LinkedIn, Gene, FDA, Partnership, Conditional sentence, Triangle Park (Quezon City), Entrepreneurship, Technology, Professor, Pharmaceutical industry, Kriyā

This acquisition serves as the foundation for Kriyas Rare Disease Division focused on the discovery and development of gene therapies for rare diseases.

Key Points: 
  • This acquisition serves as the foundation for Kriyas Rare Disease Division focused on the discovery and development of gene therapies for rare diseases.
  • This acquisition and the establishment of our Rare Disease Division align with our commitment to accelerating the advancement of best-in-class gene therapies.
  • Together with the acquisition, Warden Bio Co-Founder Kunal Kishnani is joining Kriya as President of its Rare Disease Division, where he will lead overall strategic, development, and partnership activities.
  • The company is advancing a deep and diversified pipeline of innovative gene therapies in multiple therapeutic area divisions, with current pipeline programs in ophthalmology, oncology, rare disease, and chronic disease.

Dermavant to Present New Data from Phase 3 PSOARING Program at the 2022 Winter Clinical Dermatology Conference

Retrieved on: 
Friday, January 7, 2022
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, People, Grand Promenade, Safety, QD, Acne, Atopic dermatitis, Food, Poster, Vitiligo, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Psoriasis, Skin, Therapy, Roivant Sciences, Depression, Research, Patient, Adult, Inflammatory bowel disease, PDUFA, Obesity, Quality of life, Conference, Twitter, Ageing, Week, Efficiency, PGA, Diabetes, Hypertension, LinkedIn, FDA, New Drug Application, Risk, Pharmaceutical industry, Dermavant’s Phase 3 Program for Tapinarof in Psoriasis, Psoriasis, Dermavant, DERMAVANT’S PHASE 3 PROGRAM FOR TAPINAROF IN PSORIASIS, PSORIASIS, DERMAVANT

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in Q2 2022.

Key Points: 
  • The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date in Q2 2022.
  • Dermavants pivotal Phase 3 clinical program for tapinarof in adult plaque psoriasis consists of PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980), as well as PSOARING 3 (NCT04053387), a long-term extension study.
  • Greater than 90% of eligible patients who completed PSOARING 1 and PSOARING 2 enrolled in PSOARING 3.
  • For more information, please visit www.dermavant.com , and follow us on Twitter ( @dermavant ) and LinkedIn ( Dermavant Sciences ).

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

Retrieved on: 
Thursday, January 6, 2022
Roivant Sciences, RNA transfection, Development, Biomedicine, Research, Patient, Cancer, Lymphatic system, Myelodysplastic syndrome, End-user license agreement, License, Data science, Splice, SF3B1, RNA, Sale, Sequencing, Genetic code, Intron, Nature Medicine, Pharmaceutical industry, Microdeletion syndrome, Eisai

H3B-8800 (Roivant's Development Code: RVT-2001) is a splicing modulator compound, discovered by Eisai's U.S. research subsidiary H3 Biomedicine Inc., which is undergoing development as an investigational anticancer agent.

Key Points: 
  • H3B-8800 (Roivant's Development Code: RVT-2001) is a splicing modulator compound, discovered by Eisai's U.S. research subsidiary H3 Biomedicine Inc., which is undergoing development as an investigational anticancer agent.
  • Mutations in splicing factor-encoding genes are observed in multiple hematological malignancies and solid tumors.
  • (1),(2) H3B-8800 binds to SF3B1, and demonstrated significant antitumor activity in preclinical models by modulating the disruption of mRNA splicing in cancer.
  • Eisai believes that this License Agreement with Roivant will lead to the maximization of the value of H3B-8800.

Roivant Licenses Splicing Modulator and Announces Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 5, 2022
Clinical trial, Roivant Sciences, Transfusion-dependent anemia, Securities Act of 1933, Erythropoiesis, Iron overload, Myelodysplastic syndrome, Securities Exchange Act of 1934, Patient, Environment, JPM, U.S. Securities and Exchange Commission, Conference, Risk, SF3B1, Eisai, GLOBE, NEW, MDS, Cytopenia, Fatigue, End organ damage, Dizziness, Anemia, Pharmaceutical industry, Risk management

RVT-2001 is an orally available small molecule modulator of splicing factor 3B subunit 1 (SF3B1) with over 80 human subjects exposed to date.

Key Points: 
  • RVT-2001 is an orally available small molecule modulator of splicing factor 3B subunit 1 (SF3B1) with over 80 human subjects exposed to date.
  • Roivant plans to develop RVT-2001 as a first-in-class therapy for transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (MDS).
  • Additional details on RVT-2001 and the companys development plan will be provided during Roivants presentation at the 40th Annual J.P. Morgan Healthcare Conference.
  • The presentation by Roivants chief executive officer, Matthew Gline, is scheduled for Monday, Jan. 10, 2021, at 2:15 p.m.

Full-Life Technologies Announces Senior Executive Team Appointments

Retrieved on: 
Tuesday, January 4, 2022
Health, Manufacturing, Other Manufacturing, Radiology, Pharmaceutical, Biotechnology, Radiation, Therapy, Strategic planning, University, BLA, Acquisition, Novartis, Ovarian cancer, Director, Roivant Sciences, Nuclear energy, Research, Full Life Christian Centre, Patient, Citibank, The Universe (Catholic newspaper), University of Detroit Mercy, Silicon, Biochemistry, Cranial nerve nucleus, Control, Wharton School of the University of Pennsylvania, Abbott, AREVA, General manager, Engineering, IRE, ImmunoGen, CEO, Philippe, NASDAQ, Platinum, MBA, FDA, Institute, Partner (business rank), Nuclear technology, Board, Safety, Eli Lilly, Half-life, Radiopharmaceutical, Applied science, Biotechnology, Roche, Wendell Pritchett, ADC, Management, Fine chemical, Chemistry, Gordian

Full-Life Technologies Co., Ltd. today announced four key appointments to its executive team.

Key Points: 
  • Full-Life Technologies Co., Ltd. today announced four key appointments to its executive team.
  • He noted that the core executive team also includes Full-Life co-founder and Chief Operating Officer Nicholas Wong, Ph.D.
    Dr. Chari is an internationally renowned antibody-drug conjugate (ADC) expert .
  • Mr. Sun is a seasoned life science executive with more than a decade of experience and strong track record in biotechnology.
  • Full-Life Technologies Limited is a fully integrated global Nuclear Health company headquartered in Shanghai with operations in Europe.